Cargando…
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Croatian Society of Medical Biochemistry and Laboratory Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/ https://www.ncbi.nlm.nih.gov/pubmed/31839722 http://dx.doi.org/10.11613/BM.2020.010702 |
_version_ | 1783478084235689984 |
---|---|
author | Margetić, Sandra Ćelap, Ivana Delić Brkljačić, Diana Pavlović, Nikola Šupraha Goreta, Sandra Kobasić, Ivana Lovrenčić-Huzjan, Arijana Bašić Kes, Vanja |
author_facet | Margetić, Sandra Ćelap, Ivana Delić Brkljačić, Diana Pavlović, Nikola Šupraha Goreta, Sandra Kobasić, Ivana Lovrenčić-Huzjan, Arijana Bašić Kes, Vanja |
author_sort | Margetić, Sandra |
collection | PubMed |
description | INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti-FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. MATERIALS AND METHODS: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville-sur-Oise, France) was used for quantitative determination of FXa inhibitors. RESULTS: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. CONCLUSION: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method. |
format | Online Article Text |
id | pubmed-6904970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Croatian Society of Medical Biochemistry and Laboratory Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-69049702019-12-15 Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations Margetić, Sandra Ćelap, Ivana Delić Brkljačić, Diana Pavlović, Nikola Šupraha Goreta, Sandra Kobasić, Ivana Lovrenčić-Huzjan, Arijana Bašić Kes, Vanja Biochem Med (Zagreb) Original Articles INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti-FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. MATERIALS AND METHODS: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville-sur-Oise, France) was used for quantitative determination of FXa inhibitors. RESULTS: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (< 30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. CONCLUSION: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method. Croatian Society of Medical Biochemistry and Laboratory Medicine 2019-12-15 2020-02-15 /pmc/articles/PMC6904970/ /pubmed/31839722 http://dx.doi.org/10.11613/BM.2020.010702 Text en Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Margetić, Sandra Ćelap, Ivana Delić Brkljačić, Diana Pavlović, Nikola Šupraha Goreta, Sandra Kobasić, Ivana Lovrenčić-Huzjan, Arijana Bašić Kes, Vanja Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
title | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
title_full | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
title_fullStr | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
title_full_unstemmed | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
title_short | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
title_sort | chromogenic anti-fxa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/ https://www.ncbi.nlm.nih.gov/pubmed/31839722 http://dx.doi.org/10.11613/BM.2020.010702 |
work_keys_str_mv | AT margeticsandra chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT celapivana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT delicbrkljacicdiana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT pavlovicnikola chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT suprahagoretasandra chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT kobasicivana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT lovrencichuzjanarijana chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations AT basickesvanja chromogenicantifxaassaycalibratedwithlowmolecularweightheparininpatientstreatedwithrivaroxabanandapixabanpossibilitiesandlimitations |